● Recruiting
Phase I
Oncology
A Study of MGC026 in Participants With Advanced Solid Tumors
What is being tested: MGC026, a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity in patients with advanced…
11 Aug 2026
NCT06242470